Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.09.2016 | short review

Practice changing information in aggressive lymphoma, ASH 2015

verfasst von: Dr. Michael A. Fridrik

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Summary

Out of the numerous papers dealing with lymphoma at the American Society of Hematology (ASH) 2015 meeting, three could change clinical practice. The DA-EPOCH-R regimen has improved the evidence for efficacy in Burkitt lymphoma. For lymphoproliferative disease after solid organ transplantation rituximab is a reasonable first-line treatment and nonresponders can be salvaged with R‑CHOP. For anaplastic large cell lymphoma the addition of etoposide to the CHOP regimen is an option. However, better regimens with new drugs are eagerly awaited.
Vorheriger Artikel Indolent lymphoma at ASH 2015: new treatment approaches
Nächster Artikel Focus on multiple myeloma at ASH 2015
Literatur
1.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.CrossRefPubMed
2.
Fridrik MA. (editor) Burkitt and lymphoblastic lymphoma. Rickmansworth: ESMO Press s/s/media limited; 2012.
3.
Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369(20):1915–25.CrossRefPubMedPubMedCentral
4.
Offner F, Samoilova O, Osmanov E, Eom H‑S, Topp MS, Raposo J, et al. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 2015;126(16):1893–901.CrossRefPubMedPubMedCentral
5.
Ribrag V, Tilly H, Casasnovas O, Bosly A, Bouabdallah R, Delarue R, et al. Final results of a randomized phase 2 multicenter study of two Bortezomib schedules in patients with recurrent or refractory follicular lymphoma. Groupe d’etude des Lymphomes de l’Adulte (GELA) study FL-05. Blood. 2010;116(21):768.
Metadaten
Titel
Practice changing information in aggressive lymphoma, ASH 2015
verfasst von
Dr. Michael A. Fridrik
Publikationsdatum
01.09.2016
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0271-7

Weitere Artikel der Ausgabe 3/2016

Healthcare resource utilization and G‑CSF use in patients with solid tumors or hematological malignancies hospitalized for febrile neutropenia in Bulgaria, Czech Republic and Slovakia

  • original report

Novel strategies in the management of chronic lymphocytic leukemia (CLL)

  • special report

A welcome statement from the associate Editor-in-Chief

  • editorial

Antiangiogenic therapies in ovarian cancer

  • Open Access
  • short review

Acute myeloid leukemia: highlights from ASH 2015

  • short review

Focus on multiple myeloma at ASH 2015

  • short review